進行性尿路腫瘍に対するInterleukin2(IL-2)による治療

Abstract

進行性尿路腫瘍8例にIL-2を投与し, その抗腫瘍効果, 副作用などにつき検討した.1) IL-2を28日以上投与しえた5症例のうち, 1例に膀胱癌の肝転移巣の50%以上の縮小を認めた.さらに他の1例にperformance statusの著明な改善を認めた.2) IL-2投与中に, 患者の末梢血NK, LAK活性の上昇傾向を認めた.3)主な副作用として, 発熱, 精神障害, 低血圧, 好酸球増多などを認めた.重篤な副作用として, 心不全, 腎機能障害も認められた

Eight patients with advanced cancer of the urinary tract were treated with recombinant interleukin-2(IL-2) at our department between December, 1985 and September, 1987. Patients were given 5 x 10(5)-4 x 10(6) units of IL-2 by intravenous drip infusion daily. One of five patients who received IL-2 for over 28 days showed 62% regression in size of hepatic metastasis of bladder cancer on computed tomography and another showed marked improvement of Performance Status. The upward tendency of natural killer and lymphokine-activated killer activity of peripheral blood was observed during treatment. Fever, mental disturbance, hypotension and eosinophilia and others were recognized during administration of IL-2, and cardiac failure and disturbance of renal function were also recognized as severe side effect.